<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">arthyper</journal-id><journal-title-group><journal-title xml:lang="ru">Артериальная гипертензия</journal-title><trans-title-group xml:lang="en"><trans-title>"Arterial’naya Gipertenziya" ("Arterial Hypertension")</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1607-419X</issn><issn pub-type="epub">2411-8524</issn><publisher><publisher-name>Antihypertensive League</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18705/1607-419X-2015-21-5-450-458</article-id><article-id custom-type="elpub" pub-id-type="custom">arthyper-317</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>РЕДАКЦИОННАЯ СТАТЬЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>EDITORIAL</subject></subj-group></article-categories><title-group><article-title>Интервенционные подходы к лечению артериальной гипертензии</article-title><trans-title-group xml:lang="en"><trans-title>Update on interventional approaches to treatment of hypertension</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Звартау</surname><given-names>Н. Э.</given-names></name><name name-style="western" xml:lang="en"><surname>Zvartau</surname><given-names>N. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>кандидат медицинских наук, старший научный сотрудник научно-исследовательской лаборатории патогенеза и терапии артериальной гипертензии научно-исследовательского отдела артериальной гипертензии,</p><p>ул. Аккуратова, д. 2, Санкт-Петербург, 197341</p></bio><bio xml:lang="en"><p>MD, PhD, Researcher, Department for Hypertension,</p><p>2 Akkuratov street, St Petersburg, 197341</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Конради</surname><given-names>А. О.</given-names></name><name name-style="western" xml:lang="en"><surname>Konradi</surname><given-names>A. O.</given-names></name></name-alternatives><bio xml:lang="ru"><p>доктор медицинских наук, профессор, заведующая научно-исследовательским отделом артериальной гипертензии, заместитель генерального директора по научной работе,</p><p>ул. Аккуратова, д. 2, Санкт-Петербург, 197341</p></bio><bio xml:lang="en"><p>MD, PhD, DSc, Professor, Head, Department for Hypertension, Deputy General Director on Research,</p><p>2 Akkuratov street, St Petersburg, 197341</p></bio><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru">ФГБУ «СЗФМИЦ им. В.А. Алмазова» Минздрава России<country>Россия</country></aff><aff xml:lang="en">V.A. Almazov Federal North-West Medical Research Centre<country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>22</day><month>12</month><year>2015</year></pub-date><volume>21</volume><issue>5</issue><fpage>450</fpage><lpage>458</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Звартау Н.Э., Конради А.О., 2015</copyright-statement><copyright-year>2015</copyright-year><copyright-holder xml:lang="ru">Звартау Н.Э., Конради А.О.</copyright-holder><copyright-holder xml:lang="en">Zvartau N.E., Konradi A.O.</copyright-holder><license license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://htn.almazovcentre.ru/jour/article/view/317">https://htn.almazovcentre.ru/jour/article/view/317</self-uri><abstract><p>Несмотря на широкие возможности медикаментозной терапии, необходим поиск новых подходов к лечению артериальной гипертензии (АГ), прежде всего ее резистентных форм. В кратком обзоре представлены последние данные по интервенционным методам лечения АГ. При этом основной акцент сделан не на самом изученном и активно обсуждаемом подходе — радиочастотной аблации симпатических почечных нервов (ренальной денервации), а на методах, находящихся на ранних стадиях разработки: стимуляция каротидных барорецепторов, аблация каротидного тельца, артериовенозная фистула, нейрососудистая декомпрессия, стимуляция спинного и головного мозга. Большинство данных методов влияют на уровень артериального давления опосредованно через модуляцию активности вегетативной нервной системы. Многие из них (например, ренальная денервация и стимуляция каротидных барорецепторов) являются современными модификациями применявшихся еще в прошлом веке методов лечения, в то время как другие (например, стимуляция глубинных структур головного мозга и спинного мозга, артериовенозная фистула) разрабатывались для применения при других заболеваниях. Все эти подходы пока еще очень далеки от широкого применения в клинической практике, требуют дальнейшего изучения эффективности и безопасности в рамках рандомизированных клинических исследований, технической оптимизации и выбора наиболее подходящей популяции или критериев и предикторов эффективности.</p></abstract><trans-abstract xml:lang="en"><p>In spite of availability of numerous drug treatments for arterial hypertension (HTN), there is a need for new approaches, especially in case of treatment-resistant forms. Available new interventional methods for HTN are briefly reviewed with focus on approaches in early stages of development beyond the most studied and discussed renal denervation: baroreflex activation therapy, carotid body ablation, arteriovenous fistula, neurovascular decompression, deep brain stimulation and spinal cord stimulation. Most of these approaches affect blood pressure level through modulation of autonomous nervous system activity. Some of them (e. g. renal denervation and baroreflex activation therapy) are modern technical modification of the methods which were used to treat HTN in the past century. Other methods (e.g. deep brain stimulation, spinal cord stimulation, arteriovenous fistula) were under development for other indications. All of these approaches are still far away from implementation in routine clinical practice. Further investigations of safety and efficacy in the randomized clinical studies are warranted together with technical optimization and definition of patients’ subgroup who will benefit from precise approach together with efficacy criteria and predictors.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>резистентная артериальная гипертензия</kwd><kwd>ренальная денервация</kwd><kwd>стимуляция каротидных барорецепторов</kwd><kwd>аблация каротидного тельца</kwd><kwd>артериовенозная фистула</kwd><kwd>нейрососудистая декомпрессия</kwd><kwd>стимуляция спинного и головного мозга</kwd></kwd-group><kwd-group xml:lang="en"><kwd>resistant hypertension</kwd><kwd>renal denervation</kwd><kwd>baroreflex activation therapy</kwd><kwd>carotid body ablation</kwd><kwd>arteriovenous fistula</kwd><kwd>neurovascular decompression</kwd><kwd>deep brain stimulation and spinal cord stimulation</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–1357. doi: 10.1097/01.hjh.0000431740.32696.cc</mixed-citation><mixed-citation xml:lang="en">Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M et al. Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31(7):1281–1357. doi: 10.1097/01.hjh.0000431740.32696.cc</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR et al. Hypertension treatment and control in 5 European countries, Canada, and the United States. Hypertension. 2004;43(1):10–17.</mixed-citation><mixed-citation xml:lang="en">Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR et al. Hypertension treatment and control in 5 European countries, Canada, and the United States. Hypertension. 2004;43(1):10–17.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. J Am Med Assoc. 2010;303(20):2043–50.</mixed-citation><mixed-citation xml:lang="en">Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988–2008. J Am Med Assoc. 2010;303(20):2043–50.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult to control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34(1):87–90. doi:10.1038/hr.2010.183.</mixed-citation><mixed-citation xml:lang="en">Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult to control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34(1):87–90. doi:10.1038/hr.2010.183.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766–774. doi: 10.1097/HJH.0b013e32835e2286.</mixed-citation><mixed-citation xml:lang="en">Jung O, Gechter JL, Wunder C, Paulke A, Bartel C, Geiger H et al. Resistant hypertension? Assessment of adherence by toxicological urine analysis. J Hypertens. 2013;31(4):766–774. doi: 10.1097/HJH.0b013e32835e2286.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Brinker S, Pandey A, Ayers C, Price A, Raheja P, Arbique D et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol. 2014;63 (8):834–835. doi: 10.1016/j.jacc.2013.10.067</mixed-citation><mixed-citation xml:lang="en">Brinker S, Pandey A, Ayers C, Price A, Raheja P, Arbique D et al. Therapeutic drug monitoring facilitates blood pressure control in resistant hypertension. J Am Coll Cardiol. 2014;63 (8):834–835. doi: 10.1016/j.jacc.2013.10.067</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J et al. High rates of nonadherence to antihypertensive treatment revealed by high-performance liquid chromatographytandem mass spectrometry (HP LC–MS/MS) urine analysis. Heart. 2014;100(11):855–861. doi: 10.1136/heartjnl‑2013–305063</mixed-citation><mixed-citation xml:lang="en">Tomaszewski M, White C, Patel P, Masca N, Damani R, Hepworth J et al. High rates of nonadherence to antihypertensive treatment revealed by high-performance liquid chromatographytandem mass spectrometry (HP LC–MS/MS) urine analysis. Heart. 2014;100(11):855–861. doi: 10.1136/heartjnl‑2013–305063</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013;88(10):1099–1107. doi: 10.1016/j.mayocp.2013.06.017</mixed-citation><mixed-citation xml:lang="en">Sim JJ, Bhandari SK, Shi J, Liu IL, Calhoun DA, McGlynn EA et al. Characteristics of resistant hypertension in a large, ethnically diverse hypertension population of an integrated health system. Mayo Clin Proc. 2013;88(10):1099–1107. doi: 10.1016/j.mayocp.2013.06.017</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland DT et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, populationbased cohort. Hypertension. 2014;63(3):451–458. doi: 10.1161/HYPERTENSIONAHA.113.02026</mixed-citation><mixed-citation xml:lang="en">Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland DT et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, populationbased cohort. Hypertension. 2014;63(3):451–458. doi: 10.1161/HYPERTENSIONAHA.113.02026</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet. 2012;380 (9841):591–600. doi: 10.1016/S0140–6736(12)60825–3</mixed-citation><mixed-citation xml:lang="en">Laurent S, Schlaich M, Esler M. New drugs, procedures, and devices for hypertension. Lancet. 2012;380 (9841):591–600. doi: 10.1016/S0140–6736(12)60825–3</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Lobo M, de Belder M, Cleveland T, Collier D, Dasgupta I, Deanfield J et al. Joint UK societies’ 2014 consensus statement on renal denervation for resistant hypertension. Heart. 2015;101 (1):10–16. doi:10.1136/heartjnl‑2014–307029</mixed-citation><mixed-citation xml:lang="en">Lobo M, de Belder M, Cleveland T, Collier D, Dasgupta I, Deanfield J et al. Joint UK societies’ 2014 consensus statement on renal denervation for resistant hypertension. Heart. 2015;101 (1):10–16. doi:10.1136/heartjnl‑2014–307029</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Звартау Н.Э., Зверев Д.А., Конради А.О. Ренальная денервация при резистентной артериальной гипертензии — быть или не быть? Артериальная гипертензия. 2014;20(2):155–156. doi: http://dx.doi.org/10.18705/1607–419x-2014–20–2-125–126. [Zvartau NE, Zverev DA, Konradi AO. Renal denervation in resistant hypertension — to be or not to be? Arterial’naya Gipertenziya = Arterial Hypertension. 2014;20(2):155–156. doi: http://dx.doi.org/10.18705/1607–419x-2014–20–2-125–126. In Russia].</mixed-citation><mixed-citation xml:lang="en">Звартау Н.Э., Зверев Д.А., Конради А.О. Ренальная денервация при резистентной артериальной гипертензии — быть или не быть? Артериальная гипертензия. 2014;20(2):155–156. doi: http://dx.doi.org/10.18705/1607–419x-2014–20–2-125–126. [Zvartau NE, Zverev DA, Konradi AO. Renal denervation in resistant hypertension — to be or not to be? Arterial’naya Gipertenziya = Arterial Hypertension. 2014;20(2):155–156. doi: http://dx.doi.org/10.18705/1607–419x-2014–20–2-125–126. In Russia].</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Thrasher TN. Unloading arterial baroreceptors causes neurogenic hypertension. Am J Physiol Regul Integr Comp Physiol. 2002;282(4): R1044‑R1053.</mixed-citation><mixed-citation xml:lang="en">Thrasher TN. Unloading arterial baroreceptors causes neurogenic hypertension. Am J Physiol Regul Integr Comp Physiol. 2002;282(4): R1044‑R1053.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG et al. Novel baroreflex activation therapyin resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56 (15):1254–1258.</mixed-citation><mixed-citation xml:lang="en">Scheffers IJ, Kroon AA, Schmidli J, Jordan J, Tordoir JJ, Mohaupt MG et al. Novel baroreflex activation therapyin resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010;56 (15):1254–1258.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Alnima T, Scheffers I, De Leeuw PW, Winkens B, Jongen-Vancraybex H, Tordoir JH et al. Sustained acute voltagedependent blood pressure decrease with prolonged carotid baroreflex activation in therapy-resistant hypertension. J Hypertens. 2012;30 (8):1665–1670.</mixed-citation><mixed-citation xml:lang="en">Alnima T, Scheffers I, De Leeuw PW, Winkens B, Jongen-Vancraybex H, Tordoir JH et al. Sustained acute voltagedependent blood pressure decrease with prolonged carotid baroreflex activation in therapy-resistant hypertension. J Hypertens. 2012;30 (8):1665–1670.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58(7):765–773. doi: 10.1016/j.jacc.2011.06.008</mixed-citation><mixed-citation xml:lang="en">Bisognano JD, Bakris G, Nadim MK, Sanchez L, Kroon AA, Schafer J et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011;58(7):765–773. doi: 10.1016/j.jacc.2011.06.008</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6 (2):152–158.</mixed-citation><mixed-citation xml:lang="en">Bakris GL, Nadim MK, Haller H, Lovett EG, Schafer JE, Bisognano JD. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens. 2012;6 (2):152–158.</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Hoppe UC, Brandt M–C, Wachter R, Beige J, Rump LC, Kroon AA et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6(4):270–276.</mixed-citation><mixed-citation xml:lang="en">Hoppe UC, Brandt M–C, Wachter R, Beige J, Rump LC, Kroon AA et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens. 2012;6(4):270–276.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Zhang J, Zhou S, Xu G. Carotid baroreceptor stimulation: a potential solution for resistant hypertension. Intervent Neurol. 2013;2(3):118–122. doi: 10.1159/000357167</mixed-citation><mixed-citation xml:lang="en">Zhang J, Zhou S, Xu G. Carotid baroreceptor stimulation: a potential solution for resistant hypertension. Intervent Neurol. 2013;2(3):118–122. doi: 10.1159/000357167</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Faul J, Schoors D, Brouwers S, Scott B, Jerrentrup A, Galvin J et al. Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension. J Vasc Surg. 2014;59(4):1078–1083. doi: 10.1016/j.jvs.2013.10.069</mixed-citation><mixed-citation xml:lang="en">Faul J, Schoors D, Brouwers S, Scott B, Jerrentrup A, Galvin J et al. Creation of an iliac arteriovenous shunt lowers blood pressure in chronic obstructive pulmonary disease patients with hypertension. J Vasc Surg. 2014;59(4):1078–1083. doi: 10.1016/j.jvs.2013.10.069</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Rubattu S, Calvieri C, Pagliaro B, Volpe M. Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies. J Hypertens. 2013;31(6):1061–72.</mixed-citation><mixed-citation xml:lang="en">Rubattu S, Calvieri C, Pagliaro B, Volpe M. Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies. J Hypertens. 2013;31(6):1061–72.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Hainsworth R. Cardiovascular control from cardiac and pulmonary vascular receptors. Exp Physiol. 2014;99(2):312–9.</mixed-citation><mixed-citation xml:lang="en">Hainsworth R. Cardiovascular control from cardiac and pulmonary vascular receptors. Exp Physiol. 2014;99(2):312–9.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Sinski M, Lewandowski J, Przybylski J, Bidiuk J, Abramczyk P, Ciarka A et al. Tonic activity of carotid body chemoreceptors contributes to the increased sympathetic drive in essential hypertension. Hypertens Res. 2012;35(5):487–91.</mixed-citation><mixed-citation xml:lang="en">Sinski M, Lewandowski J, Przybylski J, Bidiuk J, Abramczyk P, Ciarka A et al. Tonic activity of carotid body chemoreceptors contributes to the increased sympathetic drive in essential hypertension. Hypertens Res. 2012;35(5):487–91.</mixed-citation></citation-alternatives></ref><ref id="cit24"><label>24</label><citation-alternatives><mixed-citation xml:lang="ru">Korsheed S, EldehniMT, John SG, Fluck RJ, McIntyreCW. Effects of arteriovenous fistula formation on arterial stiffness and cardiovascular performance and function. Nephrol Dial Transplant. 2011;26(10):3296–302.</mixed-citation><mixed-citation xml:lang="en">Korsheed S, EldehniMT, John SG, Fluck RJ, McIntyreCW. Effects of arteriovenous fistula formation on arterial stiffness and cardiovascular performance and function. Nephrol Dial Transplant. 2011;26(10):3296–302.</mixed-citation></citation-alternatives></ref><ref id="cit25"><label>25</label><citation-alternatives><mixed-citation xml:lang="ru">Brouwers S, Droogmans S, Dolan E, Galvin J, Dupont A, Van Camp G et al. A prospective non-randomized open label multicenter study to evaluate the effect of an iliofemoral arteriovenous fistula on blood pressure in patients with therapyresistant hypertension. Eur Heart J. 2013;34: S654–5.</mixed-citation><mixed-citation xml:lang="en">Brouwers S, Droogmans S, Dolan E, Galvin J, Dupont A, Van Camp G et al. A prospective non-randomized open label multicenter study to evaluate the effect of an iliofemoral arteriovenous fistula on blood pressure in patients with therapyresistant hypertension. Eur Heart J. 2013;34: S654–5.</mixed-citation></citation-alternatives></ref><ref id="cit26"><label>26</label><citation-alternatives><mixed-citation xml:lang="ru">Lobo MD, Sobotka PA, Stanton A, Cockcroft JR, Sulke N, Dolan E et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet. 2015;385 (9978):1634–41.</mixed-citation><mixed-citation xml:lang="en">Lobo MD, Sobotka PA, Stanton A, Cockcroft JR, Sulke N, Dolan E et al. Central arteriovenous anastomosis for the treatment of patients with uncontrolled hypertension (the ROX CONTROL HTN study): a randomised controlled trial. Lancet. 2015;385 (9978):1634–41.</mixed-citation></citation-alternatives></ref><ref id="cit27"><label>27</label><citation-alternatives><mixed-citation xml:lang="ru">Tan ZY, Lu Y, Whiteis CA, Simms AE, Paton JF, Chapleau MW, Abboud FM. Chemoreceptor hypersensitivity, sympathetic excitation, and overexpression of ASIC and TASK channels before the onset of hypertension in SHR. Circ Res. 2010;106(3):536–545. doi: 10.1161/CIRCRESAHA.109.206946</mixed-citation><mixed-citation xml:lang="en">Tan ZY, Lu Y, Whiteis CA, Simms AE, Paton JF, Chapleau MW, Abboud FM. Chemoreceptor hypersensitivity, sympathetic excitation, and overexpression of ASIC and TASK channels before the onset of hypertension in SHR. Circ Res. 2010;106(3):536–545. doi: 10.1161/CIRCRESAHA.109.206946</mixed-citation></citation-alternatives></ref><ref id="cit28"><label>28</label><citation-alternatives><mixed-citation xml:lang="ru">Trzebski A, Tafil M, Zoltowski M, Przybylski J. Increased sensitivity of the arterial chemoreceptor drive in young men with mild hypertension. Cardiovasc Res. 1982;16(3):163–172.</mixed-citation><mixed-citation xml:lang="en">Trzebski A, Tafil M, Zoltowski M, Przybylski J. Increased sensitivity of the arterial chemoreceptor drive in young men with mild hypertension. Cardiovasc Res. 1982;16(3):163–172.</mixed-citation></citation-alternatives></ref><ref id="cit29"><label>29</label><citation-alternatives><mixed-citation xml:lang="ru">Siński M, Lewandowski J, Przybylski J, Bidiuk J, Abramczyk P, Ciarka A et al. Tonic activity of carotid body chemoreceptors contributes to the increased sympathetic drive in essential hypertension. Hypertens Res. 2012;35(5):487–491. doi: 10.1038/hr.2011.209</mixed-citation><mixed-citation xml:lang="en">Siński M, Lewandowski J, Przybylski J, Bidiuk J, Abramczyk P, Ciarka A et al. Tonic activity of carotid body chemoreceptors contributes to the increased sympathetic drive in essential hypertension. Hypertens Res. 2012;35(5):487–491. doi: 10.1038/hr.2011.209</mixed-citation></citation-alternatives></ref><ref id="cit30"><label>30</label><citation-alternatives><mixed-citation xml:lang="ru">Sinski M, Lewandowski J, Przybylski J, Zalewski P, Symonides B, Abramczyk P et al. Deactivation of carotid body chemoreceptors by hyperoxia decreases blood pressure in hypertensive patients. Hypertens Res. 2014;37(9):858–862. doi: 10.1038/hr.2014.91</mixed-citation><mixed-citation xml:lang="en">Sinski M, Lewandowski J, Przybylski J, Zalewski P, Symonides B, Abramczyk P et al. Deactivation of carotid body chemoreceptors by hyperoxia decreases blood pressure in hypertensive patients. Hypertens Res. 2014;37(9):858–862. doi: 10.1038/hr.2014.91</mixed-citation></citation-alternatives></ref><ref id="cit31"><label>31</label><citation-alternatives><mixed-citation xml:lang="ru">Winter B, Whipp BJ. Immediate effects of bilateral carotid body resection on total respiratory resistance and compliance in humans. Adv ExpMed Biol. 2004;551:15–21.</mixed-citation><mixed-citation xml:lang="en">Winter B, Whipp BJ. Immediate effects of bilateral carotid body resection on total respiratory resistance and compliance in humans. Adv ExpMed Biol. 2004;551:15–21.</mixed-citation></citation-alternatives></ref><ref id="cit32"><label>32</label><citation-alternatives><mixed-citation xml:lang="ru">Jannetta PJ, Segal R, Wolfson SK, Dujovny M, Semba A, Cook EE. Neurogenic hypertension: etiology and surgical treatment. II. Observationsin an experimental nonhuman primate model. Ann Surg. 1985;202(2):253–261.</mixed-citation><mixed-citation xml:lang="en">Jannetta PJ, Segal R, Wolfson SK, Dujovny M, Semba A, Cook EE. Neurogenic hypertension: etiology and surgical treatment. II. Observationsin an experimental nonhuman primate model. Ann Surg. 1985;202(2):253–261.</mixed-citation></citation-alternatives></ref><ref id="cit33"><label>33</label><citation-alternatives><mixed-citation xml:lang="ru">Morimoto S, Sasaki S, Miki S, Kawa T, Itoh H, Nakata T et al. Pulsatile compression of the rostral ventrolateral medulla in hypertension. Hypertension. 1997;29(1Pt2):514–518.</mixed-citation><mixed-citation xml:lang="en">Morimoto S, Sasaki S, Miki S, Kawa T, Itoh H, Nakata T et al. Pulsatile compression of the rostral ventrolateral medulla in hypertension. Hypertension. 1997;29(1Pt2):514–518.</mixed-citation></citation-alternatives></ref><ref id="cit34"><label>34</label><citation-alternatives><mixed-citation xml:lang="ru">Yamamoto I, Yamada S, Sato O. Microvascular decompression for hypertension — clinical and experimental study. Neurol Med Chir (Tokyo). 1991;31(1):1–6.</mixed-citation><mixed-citation xml:lang="en">Yamamoto I, Yamada S, Sato O. Microvascular decompression for hypertension — clinical and experimental study. Neurol Med Chir (Tokyo). 1991;31(1):1–6.</mixed-citation></citation-alternatives></ref><ref id="cit35"><label>35</label><citation-alternatives><mixed-citation xml:lang="ru">Geiger H, Naraghi R, Schobel HP, Frank H, Sterzel RB, Fahlbusch R. Decrease of blood pressure by ventrolateral medullary decompression in essential hypertension. Lancet. 1998;352 (9126):446–449.</mixed-citation><mixed-citation xml:lang="en">Geiger H, Naraghi R, Schobel HP, Frank H, Sterzel RB, Fahlbusch R. Decrease of blood pressure by ventrolateral medullary decompression in essential hypertension. Lancet. 1998;352 (9126):446–449.</mixed-citation></citation-alternatives></ref><ref id="cit36"><label>36</label><citation-alternatives><mixed-citation xml:lang="ru">Frank H, Heusser K, Geiger H, Fahlbusch R, Naraghi R, Schobel HP. Temporary reduction of blood pressure and sympathetic nerve activity in hypertensive patients after microvascular decompression. Stroke. 2009;40(1):47–51. doi: 10.1161/STROKEAHA.108.518670</mixed-citation><mixed-citation xml:lang="en">Frank H, Heusser K, Geiger H, Fahlbusch R, Naraghi R, Schobel HP. Temporary reduction of blood pressure and sympathetic nerve activity in hypertensive patients after microvascular decompression. Stroke. 2009;40(1):47–51. doi: 10.1161/STROKEAHA.108.518670</mixed-citation></citation-alternatives></ref><ref id="cit37"><label>37</label><citation-alternatives><mixed-citation xml:lang="ru">Frank H, Schobel HP, Heusser K, Geiger H, Fahlbusch R, Naraghi R. Long-term results after microvascular decompression in essential hypertension. Stroke. 2001;32(12):2950–2955.</mixed-citation><mixed-citation xml:lang="en">Frank H, Schobel HP, Heusser K, Geiger H, Fahlbusch R, Naraghi R. Long-term results after microvascular decompression in essential hypertension. Stroke. 2001;32(12):2950–2955.</mixed-citation></citation-alternatives></ref><ref id="cit38"><label>38</label><citation-alternatives><mixed-citation xml:lang="ru">Nguyen JP, Nizard J, Keravel Y, Lefaucheur JP. Invasive brain stimulation for the treatment of neuropathic pain. Nat Rev Neurol. 2011;7(12):699–709.</mixed-citation><mixed-citation xml:lang="en">Nguyen JP, Nizard J, Keravel Y, Lefaucheur JP. Invasive brain stimulation for the treatment of neuropathic pain. Nat Rev Neurol. 2011;7(12):699–709.</mixed-citation></citation-alternatives></ref><ref id="cit39"><label>39</label><citation-alternatives><mixed-citation xml:lang="ru">Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ et al. CSP 468 Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. J Am Med Assoc. 2009;301(1):63–73.</mixed-citation><mixed-citation xml:lang="en">Weaver FM, Follett K, Stern M, Hur K, Harris C, Marks WJ et al. CSP 468 Study Group. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial. J Am Med Assoc. 2009;301(1):63–73.</mixed-citation></citation-alternatives></ref><ref id="cit40"><label>40</label><citation-alternatives><mixed-citation xml:lang="ru">Basnayake SD, Hyam JA, Pereira EA, Schweder PM, Brittain JS, Aziz T et al. Identifying cardiovascular neurocircuitry involved in the exercise pressor reflex in humans using functional neurosurgery. J Appl Physiol. 2011;110(4):881–891.</mixed-citation><mixed-citation xml:lang="en">Basnayake SD, Hyam JA, Pereira EA, Schweder PM, Brittain JS, Aziz T et al. Identifying cardiovascular neurocircuitry involved in the exercise pressor reflex in humans using functional neurosurgery. J Appl Physiol. 2011;110(4):881–891.</mixed-citation></citation-alternatives></ref><ref id="cit41"><label>41</label><citation-alternatives><mixed-citation xml:lang="ru">Green AL, Wang S, Purvis S, Owen SL, Bain PG, Stein JF et al. Identifying cardiorespiratory neurocircuitry involved in central command during exercise in humans. J Physiol. 2007;578 (Pt2):605–612.</mixed-citation><mixed-citation xml:lang="en">Green AL, Wang S, Purvis S, Owen SL, Bain PG, Stein JF et al. Identifying cardiorespiratory neurocircuitry involved in central command during exercise in humans. J Physiol. 2007;578 (Pt2):605–612.</mixed-citation></citation-alternatives></ref><ref id="cit42"><label>42</label><citation-alternatives><mixed-citation xml:lang="ru">Thornton JM, Aziz T, Schlugman D, Paterson DJ. Electrical stimulation of the midbrain increases heart rate and arterial blood pressure in awake humans. J Physiol. 2002;539(Pt2):615–621.</mixed-citation><mixed-citation xml:lang="en">Thornton JM, Aziz T, Schlugman D, Paterson DJ. Electrical stimulation of the midbrain increases heart rate and arterial blood pressure in awake humans. J Physiol. 2002;539(Pt2):615–621.</mixed-citation></citation-alternatives></ref><ref id="cit43"><label>43</label><citation-alternatives><mixed-citation xml:lang="ru">Green AL, Wang S, Owen SL, Xie K, Liu X, Paterson DJ et al. Deep brain stimulation can regulate arterial blood pressure in awake humans. Neuroreport. 2005;16(16):1741–1745.</mixed-citation><mixed-citation xml:lang="en">Green AL, Wang S, Owen SL, Xie K, Liu X, Paterson DJ et al. Deep brain stimulation can regulate arterial blood pressure in awake humans. Neuroreport. 2005;16(16):1741–1745.</mixed-citation></citation-alternatives></ref><ref id="cit44"><label>44</label><citation-alternatives><mixed-citation xml:lang="ru">Carrive P, Bandler R. Control of extracranial and hind limb blood flow by the midbrain periaqueductal grey of the cat. Exp Brain Res. 1991;84(3):599–606.</mixed-citation><mixed-citation xml:lang="en">Carrive P, Bandler R. Control of extracranial and hind limb blood flow by the midbrain periaqueductal grey of the cat. Exp Brain Res. 1991;84(3):599–606.</mixed-citation></citation-alternatives></ref><ref id="cit45"><label>45</label><citation-alternatives><mixed-citation xml:lang="ru">Carrive P, Bandler R. Viscerotopic organization of neurons subserving hypotensive reactions within the midbrain periaqueductal grey: a correlative functional and anatomical study. Brain Res. 1991;541(2):206–215.</mixed-citation><mixed-citation xml:lang="en">Carrive P, Bandler R. Viscerotopic organization of neurons subserving hypotensive reactions within the midbrain periaqueductal grey: a correlative functional and anatomical study. Brain Res. 1991;541(2):206–215.</mixed-citation></citation-alternatives></ref><ref id="cit46"><label>46</label><citation-alternatives><mixed-citation xml:lang="ru">Green AL, Wang S, Bittar RG, Owen SL, Paterson DJ, Stein JF at al. Deep brain stimulation: a new treatment for hypertension? J Clin Neurosci. 2007;14(6):592–595.</mixed-citation><mixed-citation xml:lang="en">Green AL, Wang S, Bittar RG, Owen SL, Paterson DJ, Stein JF at al. Deep brain stimulation: a new treatment for hypertension? J Clin Neurosci. 2007;14(6):592–595.</mixed-citation></citation-alternatives></ref><ref id="cit47"><label>47</label><citation-alternatives><mixed-citation xml:lang="ru">Pereira EA, Wang S, Paterson DJ, Stein JF, Aziz TZ, Green AL. Sustained reduction of hypertension by deep brain stimulation. J Clin Neurosci. 2010;17(1):124–127.</mixed-citation><mixed-citation xml:lang="en">Pereira EA, Wang S, Paterson DJ, Stein JF, Aziz TZ, Green AL. Sustained reduction of hypertension by deep brain stimulation. J Clin Neurosci. 2010;17(1):124–127.</mixed-citation></citation-alternatives></ref><ref id="cit48"><label>48</label><citation-alternatives><mixed-citation xml:lang="ru">Sverrisdottir YB, Green AL, Aziz TZ, Bahuri NF, Hyam J, Basnayake SD et al. Differentiated baroreflex modulation of sympathetic nerve activity during deep brainstimulation in humans. Hypertension. 2014;63(5):1000–10. doi: 10.1161/HYPERTENSIONAHA.113.02970</mixed-citation><mixed-citation xml:lang="en">Sverrisdottir YB, Green AL, Aziz TZ, Bahuri NF, Hyam J, Basnayake SD et al. Differentiated baroreflex modulation of sympathetic nerve activity during deep brainstimulation in humans. Hypertension. 2014;63(5):1000–10. doi: 10.1161/HYPERTENSIONAHA.113.02970</mixed-citation></citation-alternatives></ref><ref id="cit49"><label>49</label><citation-alternatives><mixed-citation xml:lang="ru">Manchikanti L, Singh V, Pampati V, Smith HS, Hirsch JA. Analysis of growth ofinterventional techniquesin managing chronic pain in Medicare population: A 10-year evaluation from 1997 to 2006. Pain Physician. 2009;12(1):9–34.</mixed-citation><mixed-citation xml:lang="en">Manchikanti L, Singh V, Pampati V, Smith HS, Hirsch JA. Analysis of growth ofinterventional techniquesin managing chronic pain in Medicare population: A 10-year evaluation from 1997 to 2006. Pain Physician. 2009;12(1):9–34.</mixed-citation></citation-alternatives></ref><ref id="cit50"><label>50</label><citation-alternatives><mixed-citation xml:lang="ru">Issa ZF, Zhou X, Ujhelyi MR, Rosenberger J, Bhakta D, Groh WJ et al. Thoracic spinal cord stimulation reduces the risk of ischemic ventricular arrhythmiasin a postinfarction heart failure canine model. Circulation. 2005;111(24):3217–3220.</mixed-citation><mixed-citation xml:lang="en">Issa ZF, Zhou X, Ujhelyi MR, Rosenberger J, Bhakta D, Groh WJ et al. Thoracic spinal cord stimulation reduces the risk of ischemic ventricular arrhythmiasin a postinfarction heart failure canine model. Circulation. 2005;111(24):3217–3220.</mixed-citation></citation-alternatives></ref><ref id="cit51"><label>51</label><citation-alternatives><mixed-citation xml:lang="ru">Olgin JE, Takahashi T, Wilson E, Vereckei A, Steinberg H, Zipes DP. Effects ofthoracic spinal cord stimulation on cardiac autonomic regulation of the sinus and atrioventricular nodes. J Cardiovasc Electrophysiol. 2002;13(5):475–481.</mixed-citation><mixed-citation xml:lang="en">Olgin JE, Takahashi T, Wilson E, Vereckei A, Steinberg H, Zipes DP. Effects ofthoracic spinal cord stimulation on cardiac autonomic regulation of the sinus and atrioventricular nodes. J Cardiovasc Electrophysiol. 2002;13(5):475–481.</mixed-citation></citation-alternatives></ref><ref id="cit52"><label>52</label><citation-alternatives><mixed-citation xml:lang="ru">Linderoth B, Herregodts P, Meyerson BA. Sympathetic mediation of peripheral vasodilation induced by spinal cord stimulation: Animal studies of the role of cholinergic and adrenergic receptor subtypes. Neurosurgery. 1994;35 (4):711–719.</mixed-citation><mixed-citation xml:lang="en">Linderoth B, Herregodts P, Meyerson BA. Sympathetic mediation of peripheral vasodilation induced by spinal cord stimulation: Animal studies of the role of cholinergic and adrenergic receptor subtypes. Neurosurgery. 1994;35 (4):711–719.</mixed-citation></citation-alternatives></ref><ref id="cit53"><label>53</label><citation-alternatives><mixed-citation xml:lang="ru">Croom JE, Foreman RD, Chandler MJ, Barron KW. Cutaneous vasodilation during dorsal column stimulation is mediated by dorsal roots and CGRP. Am J Physiol. 1997;272 (2Pt2): H950–957.</mixed-citation><mixed-citation xml:lang="en">Croom JE, Foreman RD, Chandler MJ, Barron KW. Cutaneous vasodilation during dorsal column stimulation is mediated by dorsal roots and CGRP. Am J Physiol. 1997;272 (2Pt2): H950–957.</mixed-citation></citation-alternatives></ref><ref id="cit54"><label>54</label><citation-alternatives><mixed-citation xml:lang="ru">Tanaka S, Komori N, Barron KW, Chandler MJ, Linderoth B, Foreman RD. Mechanisms of sustained cutaneous vasodilation induced by spinal cord stimulation. Auton Neurosci. 2004;114 (1–2):55–60.</mixed-citation><mixed-citation xml:lang="en">Tanaka S, Komori N, Barron KW, Chandler MJ, Linderoth B, Foreman RD. Mechanisms of sustained cutaneous vasodilation induced by spinal cord stimulation. Auton Neurosci. 2004;114 (1–2):55–60.</mixed-citation></citation-alternatives></ref><ref id="cit55"><label>55</label><citation-alternatives><mixed-citation xml:lang="ru">Schultz DM, Musley S, Beltrand P, Christensen J, Euler D, Warman E. Acute cardiovascular effects of epidural spinal cord stimulation. Pain Physician. 2007;10 (5):677–685.</mixed-citation><mixed-citation xml:lang="en">Schultz DM, Musley S, Beltrand P, Christensen J, Euler D, Warman E. Acute cardiovascular effects of epidural spinal cord stimulation. Pain Physician. 2007;10 (5):677–685.</mixed-citation></citation-alternatives></ref><ref id="cit56"><label>56</label><citation-alternatives><mixed-citation xml:lang="ru">Schultz DM, Zhou X, Singal A, Musley S. Cardiovascular effects of spinal cord stimulation in hypertensive patients. Pain Physician. 2011;14 (1):1–14.</mixed-citation><mixed-citation xml:lang="en">Schultz DM, Zhou X, Singal A, Musley S. Cardiovascular effects of spinal cord stimulation in hypertensive patients. Pain Physician. 2011;14 (1):1–14.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
